The Basis for Immunological Therapy of Non-Small Cell Lung Cancer

Targeted Therapeutics Research Award
Funded equally by LUNGevity Foundation and the American Thoracic Society
Alexander Krupnick, MD
Washington University
St Louis
MO

Dr. Krupnick’s laboratory has shown that non-small cell lung cancer may develop resistance to immune-mediated destruction due to IFN gamma insensitivity. Dr. Krupnick is now investigating his hypothesis that lung cancer cells develop the ability to escape the immune system by stopping the production of IFN gamma.